It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
In 2020, almost half a million individuals developed rifampicin-resistant tuberculosis (RR-TB). We estimated the global burden of RR-TB over the lifetime of affected individuals. We synthesized data on incidence, case detection, and treatment outcomes in 192 countries (99.99% of global tuberculosis). Using a mathematical model, we projected disability-adjusted life years (DALYs) over the lifetime for individuals developing tuberculosis in 2020 stratified by country, age, sex, HIV, and rifampicin resistance. Here we show that incident RR-TB in 2020 was responsible for an estimated 6.9 (95% uncertainty interval: 5.5, 8.5) million DALYs, 44% (31, 54) of which accrued among TB survivors. We estimated an average of 17 (14, 21) DALYs per person developing RR-TB, 34% (12, 56) greater than for rifampicin-susceptible tuberculosis. RR-TB burden per 100,000 was highest in former Soviet Union countries and southern African countries. While RR-TB causes substantial short-term morbidity and mortality, nearly half of the overall disease burden of RR-TB accrues among tuberculosis survivors. The substantial long-term health impacts among those surviving RR-TB disease suggest the need for improved post-treatment care and further justify increased health expenditures to prevent RR-TB transmission.
Rifampicin-resistant tuberculosis (RR-TB) requires longer, more toxic therapy than rifampicin-sensitive disease and is associated with a higher occurrence of long-term sequelae. In this mathematical modeling study, the authors estimate that incident RR-TB in 2020 will be responsible for ~6.9 million disability-adjusted life years; 44% due to post-tuberculosis sequelae.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Harvard T. H. Chan School of Public Health, Department of Global Health and Population, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard T. H. Chan School of Public Health, Center for Health Decision Science, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
2 Stellenbosch University & Tygerberg Hospital, Division of Pulmonology, Department of Medicine, Cape Town, South Africa (GRID:grid.11956.3a) (ISNI:0000 0001 2214 904X)
3 World Health Organization, Global Tuberculosis Programme, Geneva, Switzerland (GRID:grid.3575.4) (ISNI:0000 0001 2163 3745)
4 University of Sheffield, School of Health and Related Research, Sheffield, United Kingdom (GRID:grid.11835.3e) (ISNI:0000 0004 1936 9262)
5 London School of Hygiene and Tropical Medicine, TB Modelling Group, TB Centre, London, United Kingdom (GRID:grid.8991.9) (ISNI:0000 0004 0425 469X); London School of Hygiene and Tropical Medicine, Department of Infectious Disease Epidemiology, London, United Kingdom (GRID:grid.8991.9) (ISNI:0000 0004 0425 469X)
6 Harvard T. H. Chan School of Public Health, Center for Health Decision Science, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard University, Harvard Interfaculty Initiative in Health Policy, Cambridge, USA (GRID:grid.38142.3c) (ISNI:0000 0004 1936 754X)
7 EPH, London School of Hygiene and Tropical Medicine, AMR Centre, Department of Infectious Disease Epidemiology, London, United Kingdom (GRID:grid.8991.9) (ISNI:0000 0004 0425 469X)
8 Imperial College London, National Heart & Lung Institute, London, United Kingdom (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
9 Medical Centre of the University of Munich (LMU), Division of Infectious Diseases and Tropical Medicine, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X); Partner Site Munich, German Centre for Infection Research (DZIF), Munich, Germany (GRID:grid.452463.2); German Research Center for Environmental Health (HMGU), Unit Global Health, Helmholtz Zentrum München, Neuherberg, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525)
10 Yale School of Public Health, Department of Epidemiology of Microbial Diseases, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)